Waterise and Jordan Phosphates Mines Company Announce Partnership for Innovative Deep Sea Desalination Project in the Gulf of Aqaba
12.6.2024 09:31:00 CEST | Business Wire | Press Release
European Union – Jordan Business Forum--Jordan Phosphates Mines Company (JPMC), one of the world’s largest phosphate producers, is pleased to announce a strategic partnership with Waterise, a pioneering Norwegian start-up specialising in deep sea environmentally friendly desalination. Together, they will embark on an ambitious deep sea desalination project in the Gulf of Aqaba to meet the increasing water demand at JPMC’s facilities. The two parties are currently working to secure the water off-take arrangements and other pertinent details before executing the definitive agreements.
This landmark collaboration aims to leverage Waterise’s state-of-the-art desalination solution to sustainably support JPMC's water needs, contributing to the company’s operational efficiency and environmental sustainability goals.
JPMC’s Chairman, H.E. Dr. Mohammed Thneibat, echoed this sentiment: "This partnership with Waterise aligns perfectly with our commitment to sustainable development and environmental stewardship. By utilising this innovative desalination solution we can ensure a consistent supply of water while minimising our ecological footprint. We look forward to seeing the positive impact this project will have on our operations and the surrounding community."
"We are thrilled to partner with JPMC on this groundbreaking project," said Niels Petter Wright, CEO of Waterise. "Our deep sea desalination solution based on world class oil and gas technology and marine operations represents a significant advancement in sustainable water production, and we are confident that it will provide a reliable and environmentally friendly local water supply for JPMC’s critical operations in the Gulf of Aqaba."
About JPMC
Jordan Phosphates Mines Company (JPMC) is a leading global supplier of phosphate rock and phosphate-based fertilisers. Established in 1949, JPMC has played a crucial role in the development of Jordan’s mining industry and continues to drive innovation and sustainability in the sector. With a commitment to environmental responsibility, JPMC is dedicated to enhancing the agricultural productivity and sustainability of its global customer base.
For more information, please visit www.jpmc.com.jo.
About Waterise
Waterise is a Norwegian start-up at the forefront of desalination innovation. The company has developed a revolutionary deep sea desalination solution combining proven oil and gas technologies, marine operations and reverse osmosis membranes, that offers a sustainable and efficient approach to addressing global water scarcity. Waterise’s mission is to provide fresh water in an environmentally friendly manner, supporting communities and industries around the world.
For more information, please visit www.waterise.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612161820/en/
Contacts
Steve Earl/Cameron Stone
BOLDT Partners
steve.earl/cameron.stone@boldtpartners.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press Release
ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to operational execution, but organisations cannot scale AI without trust, visibility, and control,” sai
Alvarez & Marsal utökar sin skatteverksamhet till Sverige och ingår avtal med Magnus Pantzar8.6.2026 09:00:00 CEST | Pressmeddelande
Det globala konsultföretaget Alvarez & Marsal (A&M) fortsätter att utöka sin internationella skatteverksamhet genom att etablera ett nytt kontor i Stockholm. Företaget har ingått ett avtal med Magnus Pantzar att tillträda som Managing Director och leda det svenska kontoret med planerad tillträdesdag den 1 augusti 2026. Teamet i Stockholm under Magnus ledning kommer att bistå svenska och internationella kunder däribland private equityinvesterare och portföljbolag, förvaltare av alternativa investersfonder, multinationella företag samt ägarledda och snabbväxande företag och dess nyckelpersoner. Teamet kommer att tillhandahålla transaktionsrelaterad rådgivning, fondstrukturering, allmän skattestrukturering och rådgivning inom Private Capital, såsom incitamentsprogram och värdeskapande förberedelser inför avyttring och börsintroduktion samt övrig internationell beskattning. Etableringen i Stockholm möter den växande efterfrågan från kunder på oberoende skatterådgivning. ”Sverige är ett vik
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press Release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press Release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom